风险投资视角下多发性骨髓瘤药物临床价值评估比较研究

Research on the clinical value evaluation of multiple myeloma therapeutic drugs from the perspective of venture capital

风险资本为新药项目提供了研发资金,然而不具备较高临床价值的新药项目容易导致投资失败。对于投资人,药物临床价值也包括由此产生的商业收益潜力。本文从风险投资中的临床价值评估角度,选择近2年上市的抗多发性骨髓瘤药物进行临床价值评估研究。结果表明,研究得出的投资建议与实际情况相符,并建议投资评估者应充分考虑疾病特点,且必须对有一定资历的医生进行访谈。

Venture capital has provided financial support for new drug research and development,however,new drug projects without high clinical value may result in unsuccessful investment.For investors,the clinical value of drugs includes the resulting commercial potential.Therefore,this paper evaluated the clinical value of anti-multiple myeloma drugs marketed in the last 2 years from the perspective of venture capital.As the analysis shown,the investment proposal proposed by the authors was consistent with the reality.It was suggested that the characteristics of the disease be fully considered and the doctors with certain seniority be interviewed by the investors.